
|Videos|October 1, 2015
Can Biosimilars Reduce Specialty Spending?
Author(s)Davy James, Managing Editor
David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.
Advertisement
David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Semaglutide Reduces Time in Spent in Hospital, Admission Rates in Patients With Overweight or Obesity
2
What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise
3
From the Pharmacy Counter to the Kitchen Cabinet: Helping Patients Choose Quality Supplements
4
Current Pneumococcal Vaccination Recommendations: A Clinical Update
5

























